Trial Profile
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Niacin (Primary) ; Ezetimibe; Simvastatin
- Indications Cardiovascular disorders; Dyslipidaemias
- Focus Therapeutic Use
- Acronyms AIM-HIGH
- Sponsors Axio Research Corporation
- 16 Jun 2020 Results evaluating recurrent atherosclerotic cardiovascular disease event risk by DM status in persons with known CVD on statin therapy, presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 20 Mar 2020 Results (n=2118) of this post-hoc analysis published in the American Heart Journal
- 16 Nov 2016 Post-hoc analysis results presented at the 89th Annual Scientific Sessions of the American Heart Association